This book-based activity meets the Federal training requirement of the Drug Addiction Treatment Act of 2000 (DATA 2000). Participants must have purchased and completed the Office Based Buprenorphine Treatment of Opioid Use Disorder, Second Edition. Completion will allow qualified physicians to apply for a waiver to their Drug Enforcement Administration (DEA) license, and thus to provide office-based treatment of opioid use disorder with buprenorphine. 

Development of this training was supported by the Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Service, U.S. Department of Health and Human Services. 

Note: If you prefer to complete this training online instead of in a book-based format, an online version is available.

Educational Objectives

• Discuss the rationale and need for medication-assisted treatment of opioid use disorder.
• Apply the pharmacological characteristics of opioids in clinical practice.
• Describe buprenorphine protocols for all phases of treatment and for optimal patient/treatment matching.
• Describe the legislative and regulatory requirements of office-based opioid pharmacotherapy.
• Discuss treatment issues and management of opioid use disorder in adolescents, pregnant women, and patients with acute and/or chronic pain.

Target Audience

• Physicians interested in completing the training requirement for CSAT certification to qualify for the waiver authority from the requirements of the Controlled Substances Act
• Physicians interested in learning more about office-based prescribing of buprenorphine for the treatment of opioid use disorder

Estimated Time to Complete

Estimated Duration: 8 Hours
Program Release: December 1, 2017
Program Review: December 7, 2020
Program End: December 7, 2023

How to Earn Credit

Participants who wish to earn AMA PRA Category 1 Credit™ or a certificate of participation may do so by completing all sections of the course including the evaluation. A multiple-choice quiz is provided based on the content. A passing score of 80% must be achieved. Retakes are available for the test. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (non-physicians) showing the completion date and hours earned. 

Continuing Education Credit

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The APA designates this enduring material for a maximum of 8.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The APA is one of the DATA2000 organizations that can provide the 8-hour training for physicians needed to obtain the waiver to prescribe buprenorphine. This book-based learning and complementary online assessment has been designed to meet these training requirements. Please note that the course certificate of completion is NOT your Buprenorphine Waiver, it is only your CME credit certificate. To claim your Buprenorphine Waiver, you must go to SAMSHA's "Buprenorphine Waiver Notification" website no sooner than 15 days after completing this training. Please retain this link for claiming your waiver: http://buprenorphine.samhsa.gov/forms/select-practitioner-type.php. 

Faculty and Planner Disclosures

• Daniel P. Alford, M.D., M.P.H., FACP, DFASAM, Professor of Medicine, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts
• Elie Aoun, M.D., Forensic Psychiatry Fellow, Columbia University, New York State Psychiatric Institute, New York, New York
• Jonathan Avery, M.D., Assistant Clinical Professor of Psychiatry and Assistant Dean of Student Affairs, Weill Cornell Medical Center, New York, New York
• Jeffrey D. Baxter, M.D., Associate Professor, Department of Family Medicine and Community Health, University of Massachusetts Medical School, and Chief Medical Officer, Spectrum Health Systems, Worcester, Massachusetts
• Joseph H. Donroe, M.D., Assistant Professor of Medicine, Yale University School of Medicine, New Haven, Connecticut
• Beatrice A. Eld, Consultant and former Deputy Director of Education for Addiction Psychiatry, American Psychiatric Association, Arlington, Virginia
• Saria El Haddad, M.D., Instructor in Psychiatry, Harvard Medical School, and Director, Partial Hospitalization Program, Department of Psychiatry, Brigham and Women’s Faulkner Hospital, Boston, Massachusetts
• Gerard Iru I. Fernando, M.D., Medical Director of Addiction Services, Truxtun Psychiatric Medical Group, Bakersfield, California
• David A. Fiellin, M.D., Professor of Medicine and Public Health, Yale University School of Medicine, New Haven, Connecticut
• Lynn E. Fiellin, M.D., Associate Professor of Medicine and the Child Study Center, Yale University School of Medicine, New Haven, Connecticut
• Peter D. Friedmann, M.D., M.P.H., DFASAM, FACP, Chief Research Officer and Endowed Chair for Clinical Research, Baystate Health; Associate Dean for Research and Professor of Medicine, University of Massachusetts Medical School (UMMS)—Baystate; Professor of Quantitative Health Sciences, UMMS Office of Research, Springfield, Massachusetts
• Hendrée E. Jones, Ph.D., Executive Director, UNC Horizons, and Professor, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina
• Anna T. LaRose, M.D., Instructor in Psychiatry, Boston University Medical School, and Staff Psychiatrist, VA Boston Healthcare System, Boston, Massachusetts
• Petros Levounis, M.D., M.A., Professor and Chair, Department of Psychiatry, Rutgers New Jersey Medical School, and Chief of Service, University Hospital, Newark, New Jersey
• Sharon Levy, M.D., M.P.H., Associate Professor of Pediatrics, Harvard Medical School, and Director, Adolescent Substance Abuse Program, Boston Children’s Hospital, Boston Massachusetts
• Elinore F. McCance-Katz, M.D., Ph.D., Chief Medical Officer, Rhode Island Department of Behavioral Healthcare, Developmental Disabilities and Hospitals, and Professor of Psychiatry and Human Behavior, Alpert Medical School, Brown University, Providence, Rhode Island
• Dong Chan Park, M.D., Staff Psychiatrist, Department of Psychiatry, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, Massachusetts
• Tae Woo Park, M.D., MSc, Assistant Professor of Psychiatry, Boston University School of Medicine, Boston, Massachusetts
• John T. Pichot, M.D., Private practice of psychiatry, San Antonio, Texas
• Mark T. Pichot, D.O., Psychiatry Resident (PGY-1), University of Texas Health San Antonio—Long Medical School, San Antonio, Texas
• John A. Renner Jr., M.D., Professor of Psychiatry, Boston University School of Medicine, and Associate Chief of Psychiatry, VA Boston Healthcare System, Boston, Massachusetts
• Ricardo Restrepo, M.D., M.P.H., Substance Abuse Treatment Program-SATP/Buprenorphine Clinic Medical Director VA Long Beach Healthcare System and Associate Clinical Professor at University of California, Irvine, California
• Claudia P. Rodriguez, M.D., Director of Outpatient Addiction Recovery Program, Brigham and Women’s Faulkner Hospital, and Instructor in Psychiatry, Harvard Medical School, Boston, Massachusetts
• Ximena Sanchez-Samper, M.D., Instructor, Harvard Medical School, Boston, Massachusetts, and Psychiatrist, McLean Hospital, Weston, Massachusetts
• Brad W. Stankiewicz, M.D., Addiction Psychiatry Fellow, Boston Medical Center/VA Boston Healthcare System, Boston, Massachusetts
• Eric C. Strain, M.D., Professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
• Joji Suzuki, M.D., Director, Division of Addiction Psychiatry, Department of Psychiatry, Brigham and Women’s Hospital, and Assistant Professor of Psychiatry, Harvard Medical School, Boston, Massachusetts
• Jeanette M. Tetrault, M.D., Associate Professor of Medicine, Yale University School of Medicine, New Haven, Connecticut
• Erin Zerbo, M.D., Assistant Professor, Department of Psychiatry, Rutgers New Jersey Medical School, Newark, New Jersey

Disclosure of Interests

The following contributors to this book have indicated a financial interest in or other affiliation with a commercial supporter, a manufacturer of a commercial product, a provider of a commercial service, a nongovernmental organization, and/or a government agency, as listed below:

• Peter D. Friedmann, M.D., M.P.H., DFASAM, FACP. Honorarium and travel reimbursement: Indivior Advisory Board Meeting 2015. Training: Braeburn. Consultant: Endo Pharmaceuticals. Study drug-in-kind: Alkermes
• Anna T. LaRose, M.D. Travel grant: AAAP, 2015
• Elinore F. McCance-Katz, M.D., Ph.D. Consultant: Indivior, 2015
• John A. Renner Jr., M.D. Stockholder: Johnson & Johnson, General Electric (both of which produce drugs but none that are relevant to addiction treatment). Honoraria: APA and AAP
• Eric C. Strain, M.D. Grant support: Alkermes. Consultant: Egalet Corporation, Indivior Pharmaceuticals. Advisory board: The Oak Group, Pinney Associates

No Competing Interests

The following contributors have indicated that they have no financial interests or other affiliations that represent or could appear to represent a competing interest with their contributions to this book:

Gregory Acampora, M.D.; Daniel P. Alford, M.D., M.P.H., FACP, DFASAM; Elie Aoun, M.D.; Jonathan Avery, M.D.; Jeffrey D. Baxter, M.D.; Joseph H. Donroe, M.D.; Saria El Haddad, M.D.; Beatrice A. Eld; Gerard Iru I. Fernando, M.D.; David A. Fiellin, M.D.; Lynn E. Fiellin, M.D.; Hendrée E. Jones, Ph.D.; Petros Levounis, M.D., M.A.; Sharon Levy, M.D., M.P.H.; Dong Chan Park, M.D.; Tae Woo Park, M.D., M.Sc.; John T. Pichot, M.D.; Mark T. Pichot, D.O.; Ricardo Restrepo, M.D., M.P.H.; Claudia P. Rodriguez, M.D.; Ximena Sanchez-Samper, M.D.; Brad W. Stankiewicz, M.D.; Joji Suzuki, M.D.; Jeanette M. Tetrault, M.D.; Erin Zerbo, M.D.

Reviewer Disclosures

• John Renner, M.D., Professor of Psychiatry, Boston University School of Medicine, and Associate Chief of Psychiatry, VA Boston Healthcare System, Boston, Massachusetts. Disclosures: Other: Royalties: APA Publishing for Office-Based Buprenorphine for the treatment of Opioid Use Disorder

Accessibility for Participants with Disabilities

The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.

Technical Requirements

This internet-based CME activity is best experienced using any of the following:

• The latest and 2nd latest public versions of Google Chrome, Mozilla Firefox, or Safari
• Internet Explorer 11+

This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat Reader, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:

• Browser: Google Chrome (latest and 2nd latest version), Safari (latest and 2nd latest version), Internet Explorer 11.0+, Firefox (latest and 2nd latest version), or Microsoft Edge (latest and 2nd latest version)
• Operating System: Windows versions 8.1+, Mac OS X 10.5 (Leopard) +, Android (latest and 2nd latest version), or iOS/iPad OS (latest and 2nd latest version)
• Internet Connection: 1 Mbps or higher

Minimum Requirements:

• Windows PC: Windows 8.1 or higher; 1 GB (for 32-bit)/2 GB (for 64-bit) or higher RAM; Microsoft DirectX 9 graphics device with WDDM driver; audio playback with speakers for programs with video content
• Macintosh: Mac OS X 10.5 or higher with latest updates installed; Intel, PowerPC G5, or PowerPC G4 (867MHz or faster) processor; 512 MB or higher RAM; audio playback with speakers for programs with video content

For assistance: Contact educme@psych.org for questions about this activity | Contact learningcenter@psych.org for technical assistance